ArticleOncotarget2015

18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.

Jingyi Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.